Citius Oncology to present Phase 1 LYMPHIR-pembrolizumab combo data at ASCO 2026

Citius Pharmaceuticals Inc
Tenx Keane Acquisition

Citius Pharmaceuticals Inc

CTXR

0.00

Tenx Keane Acquisition

CTOR

0.00
  • Citius Oncology flagged a Phase 1 study of LYMPHIR with Merck’s Keytruda for poster presentation at ASCO 2026.
  • Results will be presented May 30, 2026; the study tested the combination in relapsed or refractory gynecologic cancers.
  • Top-line findings showed signs of tumor shrinkage in some patients, with responses that tended to last, supporting further development interest.
  • Safety signals were described as favorable, supporting the strategy of using LYMPHIR to potentially boost checkpoint inhibitor activity beyond CTCL.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.